Fundz

Who to call at Nimbus Therapeutics, and when

Fundz watches for the moments Nimbus Therapeutics starts buying, and tells you who to reach.

  • An alert the day Nimbus Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nimbus Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nimbus Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Nimbus Therapeutics and Eli Lilly Collaborate on Research for Obesity Treatment

Jan 06, 2026

Contract Type

agreement

BostonBiotechnologyHealth CareTherapeuticsPharmaceutical

Description

Nimbus Therapeutics has entered a multi-year research collaboration and exclusive license agreement with Eli Lilly to develop a novel oral treatment for obesity and metabolic diseases. This collaboration builds on their previous efforts addressing cardiometabolic disease using computational chemistry and drug design.

Company Information

Company

Nimbus Therapeutics

Location

Boston, Massachusetts, United States

About

Nimbus Therapeutics, LLC is a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine.

Related People

Jeb
Likely contact at this company
••••••••@••••••••

See Jeb's verified email →

Peter
Likely contact at this company
••••••••@••••••••

See Peter's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Nimbus Therapeutics's next move

Learn about Strategic plan

Nimbus Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.